lab photo

Press Release

Endeavor Biomedicines licenses ULK1/2 inhibitor from Sanford Burnham Prebys and the Salk Institute

The exclusive agreement with Endeavor Biomedicines is for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1/2, a protein involved in cell recycling.
acute myeloid leukemia (AML) under microscope
Acute myeloid leukemia (AML) cancer cells viewed under a microscope.

Press Release

Researchers identify a novel player in acute myeloid leukemia

RNF5 is required for AML growth. The protein could be inhibited or used as a biomarker to improve patient outcomes.
Nature Communications logo

Paper of the Week

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors

Senior doctor breaking a cigarette

Blog

Sanford Burnham Prebys drug enters Phase 1 study for the treatment of tobacco use disorder

A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study.
PNAS logo

Paper of the Week

Clinical evidence that a dysregulated master neural network modulator may aid in diagnosing schizophrenia

Sanford Burnham Prebys Newsletter

Subscribe to our monthly email newsletter Discoveries.

 

Connect with us

Follow us on social media for the latest from Sanford Burnham Prebys.